Form 4: SOPHIA GENETICS CFO Sells Shares for Tax Withholding

SOPHIA GENETICS SA reports that Chief Financial Officer George Cardoza sold 1,403 ordinary shares to cover tax obligations related to vested restricted stock units.

Summary

• George Cardoza, Chief Financial Officer of SOPHiA GENETICS SA, sold 1,403 ordinary shares on April 8, 2026.
• The sale was conducted to satisfy tax withholding obligations arising from the vesting of restricted stock units on April 2 and 3, 2026.
• These transactions were executed under a pre-established Rule 10b5-1 trading plan.
• The shares were sold at a weighted average price of $4.8472, with individual sales ranging from $4.79 to $4.93.
• Following these sales, Cardoza beneficially owns 291,458 ordinary shares directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. While insider selling can be a negative signal, the clear explanation of tax withholding and the use of a Rule 10b5-1 plan mitigate concerns about negative sentiment.

Positives

• The sale was conducted under a Rule 10b5-1 trading plan, indicating pre-planned and non-discretionary activity.
• The sale was for tax withholding purposes, a common and expected event for executives upon vesting of equity awards.

Negatives

• A portion of the executive's equity holding was sold, which could be perceived negatively by the market, although it was for tax purposes.

Risks

• Potential for negative market perception due to insider selling, even if for tax reasons.
• The weighted average sale price of $4.8472 might indicate a lower valuation compared to previous periods, though this is not explicitly stated as a risk.

Future Outlook

No specific future outlook or guidance is provided in this Form 4 filing, which solely reports on a completed transaction.

Management Comments

• Sales were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted by the Reporting Person and do not represent discretionary trades.
• The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Industry Context

StockSavvy.ai notes that insider selling, particularly for tax withholding purposes under a Rule 10b5-1 plan, is a common occurrence for executives in the biotechnology and healthcare technology sectors as equity awards vest. This filing is routine and does not necessarily signal a change in the company's fundamental outlook.

Stakeholder Impact

• Shareholders: The sale of shares by a key executive might be viewed with caution, though the stated reason (tax withholding) is standard. The impact on share price is likely minimal given the nature of the transaction and the Rule 10b5-1 plan.
• Employees: The transaction is related to executive compensation and vesting of equity, which is a standard component of employee incentive structures.
• Creditors: No direct impact is expected.
• Suppliers: No direct impact is expected.
• Customers: No direct impact is expected.

Next Steps

• The reporting person may provide further details on specific sale prices upon written request from the issuer, security holders, or the SEC staff.

Key Dates

Keywords

SOPHIA GENETICS SA, SOPH, Form 4, Insider Trading, George Cardoza, CFO, Share Sale, Tax Withholding, Restricted Stock Units, Rule 10b5-1